Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 2:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,625 matching trials from the live ClinicalTrials.gov search.
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Conditions
Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions
Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

NCT02551549
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Pain
Interventions
Normal saline as placebo comparator, Intravenous ibuprofen
Other · Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 6 more
Conditions
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Interventions
MBS-COV, Placebo
Drug · Other
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Conditions
Primary Total Knee Arthroplasty, Intraosseous Morphine Injection, Knee Osteoarthritis
Interventions
Morphine, Vancomycin
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Conditions
Critical Illness, Delirium, Cognitive Impairment
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Hematologic Malignancies
Interventions
Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survey Administration, Electronic Health Record Review
Biological · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

NCT01169077
Conditions
Plasmodium Falciparum Malaria
Interventions
Placebo, EP-1300
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions
Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%
Drug
Lead sponsor
Waihong Chung
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Recruiting Phase 1Phase 2 Interventional

Denosumab for Type 1 Diabetes

NCT06524960
Conditions
Type 1 Diabetes
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • Indianapolis, Indiana
Conditions
Heart Failure
Interventions
Sodium Nitrite Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
Interventions
Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once
Drug · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976
Conditions
Cystitis, Interstitial
Interventions
Certolizumab pegol, Placebo
Biological · Drug
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Escondido, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Dexmedetomidine in Spine Surgery

NCT01850017
Conditions
Collapse of Thoracic Vertebra, Collapse of Lumbar Vertebrae
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hepatitis b Virus, Hepatitis B
Interventions
HepB mAb19, Sterile Saline
Biological · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Conditions
Pain
Interventions
TAP block w Liposomal bupivacaine, TAP block w normal saline
Drug · Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 2Phase 3 Interventional Results available

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

NCT04545060
Conditions
Covid19
Interventions
VIR-7831 (sotrovimab), Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
63
States / cities
Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more